|
|
Legal status
Patent expired
| (51) | INT.CL. | A61K 41/00 | (2006.01) |
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 1094839 |
| (13) | Kind of document | T |
| (96) | European patent application number | 99931229.1 |
| Date of filing the European patent application | 1999-06-30 | |
| (97) | Date of publication of the European application | 2001-05-02 |
| (45) | Date of publication and mention of the grant of the patent | 2003-05-02 |
| (46) | Date of publication of the claims translation | 2003-09-25 |
| (86) | Number | PCT/EP9904/545 |
| Date | 1999-06-30 |
| (87) | Number | WO 0000/1411 |
| Date | 2000-01-13 |
| (30) | Number | Date | Country code |
| 98202257 | 1998-07-06 | EP | |
| 98204330 | 1998-12-18 | EP |
| (72) |
VAN GINCKEL, Robert Franciscus, BE
FLOREN, Wim Joanna, Janssen Pharmaceutica N.V., BE
END, David William, Janssen Research Foundation, US
WOUTERS, Walter Boudewijn Leopold, BE
|
| (73) |
Janssen Pharmaceutica NV,
Turnhoutseweg 30, 2340 Beerse,
BE
|
| (74) |
Marius JAKULIS - JASON,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Farnezilproteintransferazės inhibitoriai, turintys radiosensibilizuojančių savybių (in vivo) |
| FARNESYL PROTEIN TRANSFERASE INHIBITORS WITH (IN VIVO) RADIOSENSITIZING PROPERTIES |
| Payment date | Validity (years) | Amount | |
| 2018-05-22 | 20 | 347.00 EUR |